Article Text

Download PDFPDF
Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study
  1. Femke H M Prince,
  2. Marinka Twilt,
  3. Nelleke C J A Jansen-Wijngaarden,
  4. Lisette W A van Suijlekom-Smit
  1. Department of Paediatrics, Erasmus MC Sophia Children’s Hospital, Rotterdam, The Netherlands
  1. Correspondence to:
    F H M Prince
    Department of Paediatrics, Sp 1545, Erasmus MC Sophia Children’s Hospital, PO Box 2060, 3000 CB Rotterdam, The Netherlands

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Etanercept is effective in juvenile idiopathic arthritis (JIA).1–,3 Currently it is administered subcutaneously at a dose of 0.4 mg/kg (maximum of 25 mg) twice a week. Clinical trials in adults show that administration of a double dose once a week is effective enough to induce and retain remission.4,5 A pharmacokinetic model developed by Yim et al6 indicates that the same dosing regimen could be used in children. Wallace7 mentions the once weekly double dose in patients with JIA, but this is not supported by clinical trials. Therefore we evaluated the efficacy of etanercept administered subcutaneously once a week at a dose of …

View Full Text


  • Competing interests: None declared.